Mirapex, Pramipexole News

Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches see the Parkinson's disease market grow at a compound annual growth rate of 2.6% over the next 10 years .

RLS patients have to decide whether a drug's benefits will outweigh its risks. The television commercials will certainly tell you: Restless legs syndrome is out there, and so are the pills to treat it.

Research and Markets: Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth © Business Wire 2009 2009-10-29 03:05:03 - ) has announced the addition of the "Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth" report to their offering.

Boehringer Ingelheim today announced that the Mirapexin /Sifrol new prolonged-release , once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA countries for the treatment of early and advanced idiopathic Parkinson's disease .

Five years after a small group of terminally ill patients pleaded with UVA for continued access to an experimental compound they believed could extend their lives, the UVA doctor who discovered the compound has left the university as mounting evidence suggests the drug is safe and, more importantly, that it may be effective against Amyotrophic ...

Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin/ Sifrol , in all countries of the European Union, Norway, Iceland and Liechtenstein.

Most of us take prescription drugs -- drugs that, by law, must be prescribed by a doctor -- at some point in our lives.